Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + axitinib
- Development stage
- Phase 2
- Lead developer
- 3D Medicines
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Envafolimab + axitinib is a combination therapy being investigated for the treatment of advanced clear cell renal cell carcinoma (ccRCC). Envafolimab is a recombinant humanized single-domain antibody (nanobody) that acts as a programmed death-ligand 1 (PD-L1) inhibitor; it is unique as the first PD-L1 inhibitor formulated for subcutaneous injection. Axitinib is an oral, potent, and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By combining immune checkpoint blockade with anti-angiogenic therapy, this regimen aims to enhance anti-tumor efficacy in treatment-naive patients with metastatic or unresectable kidney cancer. The combination is currently being evaluated in a Phase II clinical study led by Peking Union Medical College Hospital.
- Other names
- Envafolimab + Axitinib
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on envafolimab + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + axitinib.